Phathom Pharmaceuticals, Inc. (PHAT): R&D Expense
$32.78M
Year ended 2025-12-31
$30.11M
Trailing 12 months to 2026-06-30
-22.9%
3-year compound annual growth
-19.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $32.78M | -3.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $34.08M | -31.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $49.90M | -30.2% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $71.44M | -1.2% | 2024-06-14, From 2022-01-01 |
| 2021-12-31 | $72.34M | -26.3% | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | $98.15M | +381.7% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $20.37M | n/m | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $20.0K | n/a | 2020-03-19, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $32.78M | -3.8% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $17.04M | -3.8% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $258.78M | +7.1% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $1.00M | -28.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $137.92M | +54.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $17.40M | -9.5% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $167.34M | -29.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $39.28M | -17.9% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $12.43M | -25.5% |
Compare PHAT, CYRX, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗